Referência 1. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 Feb;77(2):165174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2. PMID: 28866648. 2. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double- -blind, non-inferiority trial. Lancet 2017;389:2304–16. 146
RkJQdWJsaXNoZXIy MjcxMg==